Experimental Treatments for COPD

Benralizumab (MEDI-563) is an investigational subcutaneous injection therapy for the treatment of asthma and COPD. It was studied in two Phase 3 trials, but the results showed that it failed to lower annual exacerbations in moderate to severe COPD.

Beta-alanine is a naturally occurring modified version of the amino acid alanine. It’s been shown to enhance muscular endurance, and taken orally as a supplement, may also help improve cardiovascular endurance. A preliminary study in COPD patients was completed in 2019.

BIO-11006 is an investigational 10-amino acid peptide that inhibits the phosphorylation of the MARCKS protein. It is currently in Phase 2 trials for the treatment of COPD.

CHF 5259 is an extra-fine inhaled therapy consisting of glycopyrronium (or glycopyrrolate) bromide (GB). Its active ingredient, glycopyrrolate, is a long-acting muscarinic M3 receptor antagonist. It is currently in Phase 2 testing.

CHF 5993, an investigational triple combination treatment, is a fixed-dose and fine-particle inhalation therapy consisting of beclomethasone dipropionate (BDP), formoterol fumerate (FF) and glycopyrronium bromide (GB). It is currently being studied in Phase 3 trials.

INOpulse is a nitric oxide delivery system under development as a treatment for patients with COPD with associated pulmonary hypertension, or COPD-PH. It completed a Phase 2 trial in COPD-PH patients in 2017.

Tetrahydrobiopterin (BH4) is a cofactor of the enzyme phenylalanine hydroxylase, essential to many bodily functions and one that may improve blood circulation in people with COPD.  A Phase 2 trial was completed in 2018.